TandemAI today announced the release of TandemViz ™1.0, the company’s proprietary web-based platform that provides its growing roster of drug discovery clients with a user-friendly and collaborative graphical interface to TandemAI’s suite of computational tools.

SAN DIEGO & NEW YORK & SUZHOU & SHANGHAI--(BUSINESS WIRE)--TandemAI, a technology company focused on transforming drug discovery infrastructure, today announced the appointment of Alessandro Monge, PhD, as Chief Business Officer. Dr. Monge has more than 20 years of experience in developing and deploying marketing strategies for computational technologies at established companies such as Schrödinger, as well as emerging companies, most recently at Iktos, where he was Senior Vice President and Head of US Operations.“Alessandro brings unique insights into how AI and computational tools can impact drug discovery and a wealth of experience in dealmaking with pharmaceutical and biotechnology companies,” said Jeff He, MBA, co-founder, and CEO of TandemAI. “In the CBO role, he will build on our success to date and drive TandemAI’s commercialization strategy.” He noted that TandemAI, founded in October, 2021, now has 200 employees in both the US and China, and currently serves more than 30 clients globally.“TandemAI’s integration of the most advanced computational technologies with medicinal chemistry and biology has great potential to bring unique value in drug discovery,” said Dr. Monge. “The company’s vision to dramatically lower the barrier to the world’s most advanced computational tools is inspiring and creates enormous opportunities for biotechnology and pharmaceutical partners to enhance and accelerate drug discovery through a streamlined, big data-driven process of ideation and testing.”Dr